Emerging role of NLRP3 inflammasome as a therapeutic target in cardiovascular and infectious diseases
-
Chair(s):
Na Li,
Assistant Professor,Department of Medicine, Baylor College of Medicine, Houston, TX, The United States of AmericaShigeki Miyamoto,
Associate Professor,Department of Pharmacology, University of Califonia - San Diego, San Diego, CA, The United States of America -
Session description:
Targeting the NLRP3 inflammasome for the treatment of inflammatory diseases
Dr Rebecca Coll
Lecturer in Immunobiology, Queen’s University Belfast, Belfast, United KingdomCaMKII signaling and NLRP3 inflammasome activation in cardiomyocyte mediated inflammation
Professor Shigeki Miyamoto
Associate Professor, Department of Pharmacology University of California, San Diego, San Diego, CA, The United States of AmericaOral communication speaker - to be confirmed in 2023.
Pathological role of NLRP3 inflammasome in the development of atrial fibrillation
Dr Marcel Tekook
Department of Pharmacology, University of Duisburg – Essen Germany, Essen, GermanyInflammasome activation and COVID-19 patients
Stefano Toldo Assistant Professor of Medicine, Department of Internal Medicine, Virginia Commonwealth University, Virginia, USA
Speakers
-
Dr Marcel TekookDepartment of Pharmacology, University of Duisburg – Essen Germany, Essen, Germany
-
Dr Rebecca CollLecturer in Immunobiology, Queen’s University Belfast, Belfast, United Kingdom
-
Professor Shigeki MiyamotoAssociate Professor, Department of Pharmacology University of California, San Diego, San Diego, CA, The United States of America
-
Stefano ToldoAssistant Professor of Medicine, Department of Internal Medicine, Virginia Commonwealth University, VA, USA.
Leave A Comment